New hope for hard-to-treat bone cancer: experimental drug enters human testing

NCT ID NCT07297979

First seen Jan 04, 2026 · Last updated May 16, 2026 · Updated 24 times

Summary

This early-stage trial is testing a new drug called xaluritamig in about 50 people with Ewing sarcoma, a rare bone cancer, that has returned or stopped responding to standard treatments. The main goals are to find the safest dose and check for side effects. Researchers will also measure how the drug moves through the body and whether it helps control the cancer.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EWING SARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Cedars Sinai Medical Center

    RECRUITING

    Los Angeles, California, 90048, United States

  • Chris OBrien Lifehouse

    RECRUITING

    Camperdown, New South Wales, 2050, Australia

  • Dana Farber Cancer Institute

    RECRUITING

    Boston, Massachusetts, 02215, United States

  • Perth Childrens Hospital

    RECRUITING

    Nedlands, Western Australia, 6009, Australia

  • Peter MacCallum Cancer Centre

    RECRUITING

    Melbourne, Victoria, 3000, Australia

  • University of California Los Angeles

    RECRUITING

    Los Angeles, California, 90995-1752, United States

Conditions

Explore the condition pages connected to this study.